3SAYRE EC,BUNTING PS,KOPE JA.Reliability of self-report versus chart-based prostate cancer,PSA,DRE and urinary symptoms[J].Can J Urol,2009,16(1):4463-4471.
4VENEZIANO S,PQVLICA P,COMPAGNONEG,et al.Usefulness of the(F/T)/PSA density ratio to detect prostate cancer[J].Urol Int,2005,74(5):13-18.
5TORNBLOM M,NORMING U,ADOLFSSON J,et al.Diagnostic value of percent free prostate-specific antigen:retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0ng/mL[J].Urology,1999,53:945-950.
7Jemal A, Siegel R, Xu J, et al. Cancer statistics [J]. 2010. CA Cancer J Clin, 2009, 60(5) :277-300.
8Ceriani L, Giovanella L, Salvadore M, et al. Tissue polypep-tide specific antigen (TPS) immunoassay in the diagnosis and elinineal staging of prostatic eraeinoma, comparison with pros-tate specific antigen(PSA)[J]. Int J Bid Markers, 1997, 12 (1) :27-34.
9Hilz H, Noldus J, Hammener P, et al. Molecular heterogen-tity of free PSA in sora of patients with benign and malignant prostatetumors [J]. Eur Uol, 1999, 36(4):286.
